Date: Sunday, 26 May, 2019
Location: ICC Sydney, Parkside Ballroom
Click here to view the program.
The International Neuromodulation Society is pleased to announce "Innovations in Neuromodulation. Disruptive Innovation: The Driving Force of Progress in Neuromodulation," our fifth educational event for the neuromodulation innovation and investment community which will take place on Sunday, 26 May 2019, in Sydney, Australia, as part of the official pre-conference of the INS 14th World Congress. This unique event will bring together over 200 leaders in the global neuromodulation and investment communities to share the wealth of their experiences, and their visions for the future of this exciting and rapidly evolving field.
As follows from its title, the main theme of 2019 Innovations Day is the disruptive innovation – the concept that allows us to revolutionize the field and create leaps of progress rather than incremental improvements. The last decade has been ripe with multiple examples of disruptive innovation in the neuromodulation arena, including "out-of-box" stimulation targets, frequencies, paradigms and principles.
To fit in with the day's theme, we will have lectures from innovators and entrepreneurs on technology disruption, interspersed with emerging company panels that will highlight how each company's technology or approach has disrupted the status quo and what this means for the company and the neuromodulation space. This will provide engaging sessions for attendees of all backgrounds who are interested in the neuromodulation space and where technology and therapies are going.
We have developed the program with an aim of achieving several objectives:
- Identify and discuss the data that needs to be collected by commercializing companies to ensure it has utility for future approval and reimbursement applications.
- Learn about the process by which innovations occur, become funded, are approved, receive reimbursement and reach the marketplace.
- Describe the process of establishing and protecting intellectual property.
- Define the regulatory process by which approvals are obtained in Australia, Europe and in the U.S., respectively, and ultimately earn full reimbursement.
- Learn about what public scientific initiatives are available with which to partner.
- Find out about current and future investment strategies and challenges in the device market – in Australia, Europe and the US.
- Discover emerging companies and the science behind their innovative therapies.
- Network with the leaders in innovation, investment, basic science and clinical practice in the neuromodulation space.
We encourage you start making your plans, and register to attend the pre-conference in addition to the main INS Congress here.
Start-ups are Invited to Apply to Showcase their Companies and Technology
In this Innovations Day, INS is presenting an opportunity for innovators to share their company stories with venture capitalists, clinicians, engineers and other Industry members. Following the day's theme, we would ask selected participants to talk about how their company's technology or approach has disrupted the status quo and what this means for the company and the neuromodulation space. For example, the unique way that a therapy is developed and delivered, or a medical condition viewed and treated. The day will include multiple panels and talks, with the promise to all willing participants to get platform time either individually or as a part of panel discussion.
In addition to the presenters, we have invited senior Venture Capital investors from a number of major companies in attendance as well as a number of Australian VC companies. This will be an excellent opportunity for emerging companies to showcase their achievements, create new contacts, learn from their peers, gauge their progress and, as a result, become more competitive and successful! This will provide engaging sessions for attendees of all backgrounds who are interested in the neuromodulation space and where technology and therapies are going.
Start-ups who are interested should submit their application as soon as possible, as space is limited. Companies selected to participate in the panels will receive a tabletop exhibit in the session room for the day.* A list of previous participating companies and investors is posted below.
Please contact the INS Executive Office with any questions about
participating in the pre-conference or exhibiting in the main congress.
We hope to see you in Sydney!
Dr. Konstantin Slavin
INS Secretary
Co-Chair, INS Innovations in Neuromodulation
Dr. Marc Russo
INS Director-at-Large
Co-Chair, Innovations in Neuromodulation
Chair, INS 14th World Congress
* Each company selected to participate in the emerging company panels will be kindly requested to provide a $2,000 US unrestricted grant to the International Neuromodulation Society, a 501(c)3 nonprofit organization.
LINKS:
Emerging Company Application for Innovations in Neuromodulation
Main Congress Sponsor and Exhibitor Prospectus
#INS2019
Previous Participating Companies
INS 2017 – Edinburgh
Bioinduction Ltd
BlueWind Medical
Clearly Present Foundation
G-Therapeutics
GiMer Medical
Helius Medical Technologies
Mainstay Medical
MicroTransponder
NeuroNano
Ripple
Theranica Bio-Electronics Ltd.
WISE Srl
Wyss Center for Bio & Neuroengineering
INS 2015 – Montreal
Axonics Modulation Technologies
BlueWind Medical
CorTec
FemPulse LLC
Lungpacer Medical Inc.
Medtronic Eindhoven Design Center, formerly Sapiens Steering Brain
Stimulation
MicroTransponder
Neuronano AB
Neuros Medical
SPR Therapeutics
WISE Srl
INS 2013 – Berlin
Aleva Neurotherapeutics
Algostim
Biotectix
Endostim
Functional Neuromodulation
Mainstay Medical
NeuroNexus
Neuros Medical
NeuroSigma
Neurotargeting
Nexstim Oy
Sapiens Steering Brain Stimulation
Stimwave Technologies
WISE Srl
INS 2011 – London
Autonomic Technologies
Cerebral Rx
Functional Neuromodulation
ImThera Medical
NDI Medical
Neuros Medical
Nevro Corp.
QiG Group / Algostim
Spinal Modulation
Previous Participating Investors
INS 2017 – Edinburgh
Action Potential Venture Capital
INS 2015 – Montreal
Fountain Healthcare Partners
Greatbatch
JJDC Investors
J&J Innovation
Venture Investments MD & D
INS 2011 – London
Accuitive Medical Ventures, United States
Edmond de Rothschild Investment Partners, France
IJ Partners SA, Switzerland
HealthCap, Sweden
Sofinnova Partners, France
Third Rock Ventures, United States
Three Arch Partners, United States
